Stock On the Run: Paratek Pharmaceuticals inc (NASDAQ:PRTK)

Paratek Pharmaceuticals inc (NASDAQ:PRTK) currently has a “Hold” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Hold” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.

Paratek Pharmaceuticals inc (NASDAQ:PRTK) lost -0.95 Percent and closed its previous trading session at $10.45. The stock traded with the average Volume of 612.06 Million at the end of last session.

Paratek Pharmaceuticals inc (NASDAQ:PRTK) has the Market Capitalization of 330.12 Million. The Stock has its 52-week High of $29.00 and 52-Week Low of $ 9.38 and it touched its 52-week high on 08/31/17 and 52-Week Low on 08/03/18


The company reported its last earnings Actual EPS of $-0.94/share. While, the analyst predicted that the company could provide an EPS of $-0.93/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.01/share which shows an Earnings Surprise of -1.1 Percent.

Sell side analysts plays vital role in buying and selling a stock where 3 analysts rated Paratek Pharmaceuticals inc (NASDAQ:PRTK) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.

The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 0.5% where SMA50 and SMA200 are -0.33% and -26.9% respectively.

The company shows its Return on Assets (ROA) value of -47.2%. The Return on Equity (ROE) value stands at -106.4%. While it’s Return on Investment (ROI) value is -60.2%.

Paratek Pharmaceuticals inc (NASDAQ:PRTK) currently has a Weekly Volatility of 9.55% percent while its Monthly Volatility is at 4.94% percent. While talking about Performance of the Stock, Paratek Pharmaceuticals inc currently has a Weekly performance of 6.09%, monthly performance percentage is 1.46 percent, Quarterly performance is -4.57 percent, 6 months performance shows a percent value of -17.72% and Yearly Performance is -48.9 percent.

Company Profile:

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States.